Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06230354 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Study acronym: RACEMATE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 29, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Oct 2025 to Sep 2026 Trial status: Enrolling by Invitation to Active, Not Recruiting · Enrollment target: estimated 66 to confirmed 42 · Study sites: 13 to 12 · 4 morev5 Show 7 more changesShow less
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 66 to confirmed 42
    • Study sites: 13 to 12
    • Start date changed from estimate of May 2024 to May 15, 2024
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints revised (11)
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria expanded, about 3 wordsv4 See this version in full on ClinicalTrials.gov ↗
  3. Start date: Jan 31, 2024 to May 2024 Enrollment target: 62 to 66 · Study sites: 16 to 13 · Primary and study completion dates: Sep 2025 to Oct 2025 · 3 morev3 Show 6 more changesShow less
    • Enrollment target: 62 to 66
    • Study sites: 16 to 13
    • Primary and study completion dates: Sep 2025 to Oct 2025
    • Eligibility criteria expanded, about 97 words
    • Secondary endpoints: details revised at 1 of 11 entries
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date changed from estimate of Jan 2024 to Jan 31, 2024 · Secondary endpoints: details revised at 1 of 11 entries · Site contacts updated at 15 of 16 sitesv2 Show 3 more changesShow less
    • Start date changed from estimate of Jan 2024 to Jan 31, 2024
    • Secondary endpoints: details revised at 1 of 11 entries
    • Site contacts updated at 15 of 16 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).
Trial Details
NCT Number NCT06230354
Lead Sponsor Imperial College London
Collaborators: AstraZeneca
Conditions EGPA - Eosinophilic Granulomatosis With Polyangiitis
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov